MENU

Should you buy these beaten down ASX shares?

Although the market has pushed higher this week to multi-year highs, not all shares on the market are faring as well.

Three shares which have fallen significantly over the last 12 months are listed below. Are they worth buying today?

The Accent Group Ltd (ASX: AX1) share price has fallen 40% since this time last year, leaving its shares trading at just 12x trailing earnings. While profit growth is expected to be minimal this year, I still think its shares are trading at an attractive price. Especially when you factor in the trailing fully franked 6.5% dividend that they provide. This could make it worth considering Accent today in my opinion.

The Freelancer Ltd (ASX: FLN) share price has tumbled 50% lower during the last 12 months. Investors appear to have run out of patience with the operator of the largest freelance network after slower than expected growth. Quarterly cash receipts have been mostly flat for nearly two years now, leaving many concerned (myself included) that it may take many years before it is making meaningful profits. I would stay clear of Freelancer until things improve.

The Mayne Pharma Group Ltd (ASX: MYX) share price has lost 47% of its value since this time last year. The pharmaceutical company has come under pressure due to significant price deflation in the U.S. generic drugs market. This has been caused by the consolidation of wholesalers and retail pharmacy chains, leading to around four purchasers controlling upwards of 90% of the supply. The good news is that this can’t carry on forever and a turnaround in prices is inevitable. The big question, though, is when will it happen? As it is hard to say, I intend to stay away from Mayne Pharma until it is evident in its sales.

Rather than risk money in Mayne Pharma, I would suggest investors check out these top blue-chip shares.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!